1722 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma

Page last updated: 19 October 2022

Application Detail

Description of Medical Service

Axicabtagene ciloleucel is a CAR T-cell product produced using a patient’s own T-cells, making the product unique to each patient. A patient’s T-cells are collected via a process called leukapheresis. The T-cells are genetically modified in a lab to express an anti-CD19 chimeric antigen receptor (CAR) which targets the lymphoma B-cells. Following modification and subsequent proliferation, the T-cells are infused back into the patient where they target and kill the lymphoma B-cells.

Description of Medical Condition

Large B-cell lymphoma (LBCL) is a collection of entities that are subtypes of non-Hodgkin’s lymphoma. LBCL accounts for roughly one third of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease or both.

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1204 KB)
Application Form (Word 415 KB)

Consultation Survey

Consultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application


Bypassing PASC


9-10 February 2023


30-31 March 2023